Dr. Oz Joins Biotechnology Firm PanTheryx' Board

By Barbara Wenger

Dr. Mehmet Oz, the host of The Dr. Oz Show, has been appointed to the board of biotechnology company, PanTheryx.

Oz is vice-chair and professor of Surgery at Columbia University where he directs the Cardiovascular Institute and Complementary Medicine Program at New York Presbyterian Hospital, and has authored over 400 original publications, including seven New York Times Best Sellers. He has received several patents, and performs more than 100 heart surgeries per year.

“We’re thrilled to have Dr. Mehmet Oz join us on the board of directors,” said Mark Braman, CEO of PanTheryx. “As a company, we are committed to unlocking the vast health and therapeutic benefits of bovine colostrum through robust clinical science. Dr. Oz’s insight and guidance will be pivotal in helping us to reach that goal.”

PanTheryx was founded in 2007 to create nutritional solutions for pediatric infectious diarrhea, the second leading killer of children under the age of five in the developing world. The company has evolved to leverage the cellular and biomolecular processes of bovine colostrum to develop and commercialize a wide range of nutritional interventions and first-in-class therapeutics for conditions such as C. difficile infections, Crohn’s Disease, Ulcerative Colitis, and GI-related side effects of cancer therapies such as mucositis.

“I’m excited to be joining PanThereyx’s board at such an important time in the company’s development,” said Dr. Mehmet Oz. “Research and real-world experienced point to the pivotal role our gut plays in maintaining and restoring health. It is essential to overall well-being. Through the innovative use of colostrum, PanTheryx is pioneering the development of nutrition-based interventions and biologics to dramatically improve global health safely and effectively.”